Evorel (estradiol transdermal) / J&J - LARVOL DELTA

Real-World Primary Care Data on Menopause: Insights into Diagnoses, Treatment Patterns, and Care Gaps (ISPOR 2025) - "Most common treatments among the 133 patients receiving prescriptions were Estradiol 10 microgram pessaries (n=31), Estriol 0.01% vaginal cream with applicator (n=11), and Estradiol 50mcg/24hours/Norethisterone 170mcg/24hours transdermal patches (n=10).336 patients were identified with perimenopausal codes (median age 52.5, range 34-84), of whom 80% had no recorded/prescribed medications. Among the 65 treated patients, the most common were Progesterone micronised 100mg capsules (n=16), Estradiol 0.06% transdermal gel (750 microgram per actuation) (n=13), and Generic Evorel Sequi transdermal patches (n=12).At the largest site, prescription rates were 22% (77/349) for menopause and 42% (58/139) for perimenopause patients... The findings reveal that most patients lacked prescribed/ recorded medications in primary care, aligning with previous publications of limited awareness and support for menopausal patients and suggesting a potential care gap. Medication data,..."

Clinical • Real-world • Real-world evidence

Pubertal induction amongst girls with Turner Syndrome: oral vs patch oestrogen over the last 16 years (ESPE 2024) - "Induction of puberty with oral or patch oestrogen appears to be equally effective in girls with TS. USS and DEXA scans were not consistently undertaken."

Genetic Disorders • Turners Syndrome

Navigating the microbial community in the trachea-oropharynx of breast cancer patients with or without neoadjuvant chemotherapy (NAC) via endotracheal tube: has NAC caused any change? (PubMed, PeerJ) - "Here, we provide the first comparison data of the respiratory tract microbiome of breast cancer patients with or without NAC via NGS analysis. This study ultimately seeks to contribute to future studies on the lower respiratory tract in cancer patients with cytotoxic chemotherapy by establishing reliable control data."

Journal • Breast Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor

"https://t.co/myEzKQcUDu #iwishicouldbeplayingwithhishairrightnow @Shimha18 @GuerillaSA @KeckMedUSC @KECKSchool_USC @USCneurorads @USC_Rads @RadiologyUSC @USCRadResearch @USC_ERad @ashishkjha @iko_uwais @vince_uy @trevorellestad" (@emergencyexit21)

Impact of micronised progesterone and medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed with premature ovarian insufficiency or an early menopause: a randomised pilot trial. (PubMed, Maturitas) - "The positive changes in traditional markers were not reflected in the cardiogenic biomarker, cfPWV, which has demonstrated a higher positive predictive value for cardiovascular events than traditional measurements."

Combination therapy • Journal • Cardiovascular • Women's Health

Variability of response to early puberty induction demonstrated by transverse uterine diameter measurement and a novel method of 3D breast imaging. (PubMed, Clin Endocrinol (Oxf)) - "We demonstrate variation in response to exogenous oestrogen, emphasising the necessity for individualised dose titration. In the absence of sensitive oestradiol assays, uterine transverse measurements may be used as a surrogate marker of oestrogen sensitivity to guide early dose adjustment. 3D breast imaging may provide a quantitative assessment of breast development to complement Tanner breast staging."

Journal • Endocrine Disorders • Gynecology • Pediatrics

"@JNJNews EN DONDE PODRÍA CONSEGUIR EL HORMONAL EVOREL 25 EN MEXICO?" (@MexCamin)

A randomised controlled trial assessing the effect of micronised progesterone versus medroxyprogesterone acetate on the coagulation cascade of women with premature ovarian insufficiency (ESHRE 2019) - "44 (21 randomised to Utrogestan; 23 to MPA) underwent sampling at baseline and 3-months for thrombin generation. Wider implications of the findings: The absence of statistically significant changes in the global coagulation assay confers no additional adverse effect with either progestogen preparation when combined with transdermal oestrogen in the management of women with POI. This finding helps create an evidence-based choice for women without increasing their overall thrombotic risk."

Clinical

A randomised controlled trial assessing the effect of micronised progesterone versus medroxyprogesterone acetate on the coagulation cascade of women with premature ovarian insufficiency (ESHRE 2019) - "44 (21 randomised to Utrogestan; 23 to MPA) underwent sampling at baseline and 3-months for thrombin generation. Wider implications of the findings: The absence of statistically significant changes in the global coagulation assay confers no additional adverse effect with either progestogen preparation when combined with transdermal oestrogen in the management of women with POI. This finding helps create an evidence-based choice for women without increasing their overall thrombotic risk."

Clinical

A randomised controlled trial assessing the effect of micronised progesterone versus medroxyprogesterone acetate on the coagulation cascade of women with premature ovarian insufficiency (ESHRE 2019) - "44 (21 randomised to Utrogestan; 23 to MPA) underwent sampling at baseline and 3-months for thrombin generation. Wider implications of the findings: The absence of statistically significant changes in the global coagulation assay confers no additional adverse effect with either progestogen preparation when combined with transdermal oestrogen in the management of women with POI. This finding helps create an evidence-based choice for women without increasing their overall thrombotic risk."

Clinical

A randomised controlled trial assessing the effect of micronised progesterone versus medroxyprogesterone acetate on the coagulation cascade of women with premature ovarian insufficiency (ESHRE 2019) - "44 (21 randomised to Utrogestan; 23 to MPA) underwent sampling at baseline and 3-months for thrombin generation. Wider implications of the findings: The absence of statistically significant changes in the global coagulation assay confers no additional adverse effect with either progestogen preparation when combined with transdermal oestrogen in the management of women with POI. This finding helps create an evidence-based choice for women without increasing their overall thrombotic risk."

Clinical

"Evorel patches contain synthetic progesterone which is not the gold standard. I would always recommend body-identical Uterogestan, which has the best risk profile, including breast cancer, and rarely causes any progestogenic side effects - unlike synthetics. 👍" (@GynaeExpert)

Adverse events • Gold Standard